Quiver ai summary immatics n.v Immatics intends to advance ima401 further through clinical development. Announced promising results from its phase 1a dose escalation trials for two tcr bispecifics, ima402 and ima401, targeting advanced solid tumors
Corinna Kopf Onlyfans Leaked Corrina Youtuber Leaking
During a conference call on november 12, 2025, the company highlighted that ima402 demonstrated a 30% confirmed objective response rate (corr) in melanoma and deep responses in ovarian carcinoma, while ima401 showed a.
Based on the terms of the agreement with bristol myers squibb, immatics has been responsible for conducting the ongoing phase 1 clinical trial
